Literature DB >> 15163206

Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H3 receptor lacking a nitrogen atom in the side chain.

Nadia Pelloux-Léon1, Abdellatif Fkyerat, Antonia Piripitsi, Wasyl Tertiuk, Walter Schunack, Holger Stark, Monique Garbarg, Xavier Ligneau, Jean-Michel Arrang, Jean-Charles Schwartz, C Robin Ganellin.   

Abstract

4-(3-Aryloxypropyl)-1H-imidazoles, which possess a meta-positioned substituent in the aryl ring, have been synthesized and tested for activity at histamine H(3) receptors. The compounds having a CN, Me, or Br substituent were found to be antagonists, whereas CF(3), Et, i-Pr, t-Bu, COCH(3), or NO(2) substituents remarkably afforded partial agonists when tested in vitro on rat cerebral cortex synaptosomes for inhibition of [(3)H]histamine release. The compounds were also active in vivo, and furthermore, the CF(3)-substituted compound trifluproxim (UCL 1470, 7) acted as a potent full agonist in vivo, having ED(50) = 0.6 +/- 0.3 mg/kg per os in mice for inhibition of brain N(tau)-methylhistamine formation. Related structures have also been investigated; homologues 4-[4-(3-(trifluoromethyl)phenoxy)butyl]-1H-imidazole and 4-[2-(3-(trifluoromethyl)phenylthio)ethyl]-1H-imidazole are shown to be partial agonists, whereas the O isostere 4-[2-(3-(trifluoromethyl)phenoxy)ethyl]-1H-imidazole is an antagonist as is the S homologue 4-[3-(3-(trifluoromethyl)phenylthio)propyl]-1H-imidazole and its CH(2) isostere 4-[4-(3-(trifluoromethyl)phenyl)butyl]-1H-imidazole.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163206     DOI: 10.1021/jm031141p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

1.  4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity.

Authors:  Gábor Wágner; Tamara A M Mocking; Marta Arimont; Gustavo Provensi; Barbara Rani; Bruna Silva-Marques; Gniewomir Latacz; Daniel Da Costa Pereira; Christina Karatzidou; Henry F Vischer; Maikel Wijtmans; Katarzyna Kieć-Kononowicz; Iwan J P de Esch; Rob Leurs
Journal:  J Med Chem       Date:  2019-11-20       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.